Automate Your Wheel Strategy on ALT
With Tiblio's Option Bot, you can configure your own wheel strategy including ALT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALT
- Rev/Share 0.0002
- Book/Share 1.9805
- PB 1.8556
- Debt/Equity 0.0982
- CurrentRatio 20.4362
- ROIC -0.5163
- MktCap 324345578.0
- FreeCF/Share -1.0013
- PFCF -3.9757
- PE -3.4125
- Debt/Assets 0.0833
- DivYield 0
- ROE -0.6263
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ALT | Goldman | -- | Sell | -- | $1 | July 10, 2025 |
| Initiation | ALT | William Blair | -- | Market Perform | -- | -- | Feb. 28, 2025 |
| Initiation | ALT | Stifel | -- | Buy | -- | $18 | Jan. 8, 2025 |
News
Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)
Published: August 15, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 15, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class Period may, no later than October 6, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Read More
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
Published: August 15, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. ("Altimmune" or the "Company") …
Read More
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT
Published: August 15, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025.
Read More
These Analysts Slash Their Forecasts On Altimmune Following Q2 Results
Published: August 13, 2025 by: Benzinga
Sentiment: Negative
Altimmune, Inc. ALT posted a loss for the second quarter on Tuesday.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Altimmune, Inc. (ALT) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that the Company consistently touted its inflated expectations for positive topline results from the IMPACT Phase 2b MASH trial, while concealing higher responses in the placebo group, which they knew or should have known would negatively impact the topline results.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Berger Montague PC Investigating Claims on Behalf of Altimmune, Inc. (NASDAQ: ALT) Investors After Class Action Filing
Published: August 12, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of Altimmune between August 10, 2023 through June 25, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class Period may, no later than October 6, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Published: August 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Shareholders of Altimmune, Inc. Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Altimmune Board of Directors Appoints Jerry Durso as Chairman
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH
Read More
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: August 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 10, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period").
Read More
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Published: August 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2025.
Read More
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Published: August 07, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025. Altimmune describes itself as a “clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Alleg.
Read More
Altimmune, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 6, 2025 Deadline to file Lead Plaintiff Motion.
Published: August 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Published: August 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Altimmune, Inc. (ALT)
Published: August 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all persons or entities who purchased the securities of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the “Class Period”).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: July 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm
Published: July 19, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $ALT--ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: July 07, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: July 02, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts
Published: June 27, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Altimmune, Inc. ALT released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
Read More
Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide
Published: June 26, 2025 by: Seeking Alpha
Sentiment: Positive
Altimmune, Inc.'s pemvidutide met the primary endpoint of MASH resolution in phase 2b IMPACT study which sets it on a continued development path going forward. The short 24-week trial duration likely limited fibrosis results; longer studies could achieve statistical significance with this endpoint supporting a continued path for phase 3 development. Pemvidutide uniquely delivers both MASH resolution and weight loss, with the lowest adverse event-related discontinuation rates, giving it strong competitive advantages.
Read More
About Altimmune, Inc. (ALT)
- IPO Date 2017-05-26
- Website https://altimmune.com
- Industry Biotechnology
- CEO Vipin K. Garg
- Employees 59